AIT Therapeutics Announces Human and In-Vitro Nitric Oxide Data to be Presented at the 3rd Annual World Bronchiectasis Conference
Two presentations to highlight the direct killing effect of nitric oxide and the use of the nitric oxide generator and delivery system as a potential therapy for Mycobacterium abscessus complex (MABSC) lung infection
NEW YORK, June 27, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that in-vitro data as well as data from a compassionate use study will be presented at the 3rd Annual World Bronchiectasis Conference being held at Georgetown University in Washington, D.C. on July 12-14, 2018.
“The nitric oxide used to treat the cystic fibrosis patient with refractory MABSC came from our proprietary NO generator and delivery system. Our in-vitro data provide valuable confirmation of the direct killing power of NO,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics. “With our NO generator and delivery system successfully used in a real-world setting, we are well on our way to effectively treat patients in their homes for chronic, severe, refractory bacterial lung infections.”
The first poster, entitled: “High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterium abscessus Lung Infection in Cystic Fibrosis,” demonstrates the antibacterial activity of exogenous NO against multi-drug resistant Mycobacterium abscessus clinical strains in vitro.
The second poster, entitled: “Treatment of Refractory Mycobacterium abscessus Lung Infection with Inhaled Intermittent Nitric Oxide,” demonstrates inhaled nitric oxide was associated with clinical improvement but not microbiologic improvement in a cystic fibrosis patient with refractory Mycobacterium abscessus infection and may be a viable treatment option.
Both posters will be available for viewing on Friday, July 13 at 11:45 a.m. to 1:20 p.m., and then again from 3:45 p.m. to 5:00 p.m.
About Mycobacterium abscessus complex (MABSC) of the Lungs
MABSC is the most aggressive and difficult to treat species of nontuberculous mycobacteria (NTM). There are currently no approved treatments for MABSC. Current standard-of-care is a cocktail of antibiotics that often proves to be ineffective with severe adverse effects. Most patients suffering from MABSC have an underlying disease, such as cystic fibrosis or chronic obstructive pulmonary disease (COPD). The median survival of those suffering from MABSC is less than 5 years.
About Nitric Oxide (NO)
Nitric Oxide (NO) is a powerful molecule proven to play a critical role in a broad array of biological functions. In the airways, NO is believed to play a key role in the innate immune system at concentrations of approximately 200 ppm. In vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, both gram-positive and gram-negative, but also against other diverse organisms including mycobacteria, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.
About the 3rd Annual Bronchiectasis Conference
The Conference is a focused, cutting-edge gathering of the world’s experts on bronchiectasis and nontuberculous mycobacterial lung infections. Highlights of the conference include presentations of the most up to date research on disease mechanisms in bronchiectasis, including new understandings on the role of inflammation, infection and the microbiome. Clinical topics will include sessions on the diagnosis and treatment of bronchiectasis and NTM infections, including small group, case-based presentations specifically aimed at understanding the role of airway clearance, anti-inflammatory treatments and antibiotics.
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company using nitric oxide (NO) to treat respiratory and other diseases. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care, as well as pulmonary hypertension, in various settings. AIT Therapeutics is currently advancing its revolutionary NO Generator and Delivery System in clinical trials for the treatment of bronchiolitis and severe lung infections such as nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
This press release contains “forward-looking statements.” Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” “likely,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; and our short operating history. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.
Steven Lisi, Chief Executive Officer
AIT Therapeutics, Inc.
LifeSci Advisors, LLC
Released June 27, 2018